Basel (Switzerland) and Mannheim (Germany), May 19, 2016 – VAXIMM AG, a Swiss-German biotech company focused on developing oral T-cell immunotherapies, today announced that data with its lead product candidate VXM01 in pancreatic cancer will be presented at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 3-7, 2016 in Chicago, Illinois.
Dr. Jarl Jungnelius, Chief Medical Officer of VAXIMM, will present the poster. The abstract is now available on the ASCO website. Abstract #3091 A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGF-receptor 2, in patients with advanced pancreatic cancer. To see the abstract, please click here.
Details about the presentation:
Date and Time: Sunday, June 5, 2016, 8:00-11:30 AM
Poster Session: Developmental Therapeutics—Immunotherapy
Location: Hall A Abstract #3091
VXM01 is an oral T-cell immunotherapy that targets the tumor-specific vasculature and certain immune-suppressive cells. It is based on a live attenuated, safe, orally available, bacterial vaccine strain, which is modified to carry vascular endothelium growth factor receptor-2 (VEGFR-2) as the target gene. VXM01 stimulates the patient’s immune system to activate VEGFR-2-specific, cytotoxic T-cells (so-called killer cells). These immune killer cells then actively destroy the cells in the tumor vasculature leading to an increased infiltration of various immune cells into the tumor. In pre-clinical studies, a murine analog VXM01 vaccine has shown broad anti-tumor activity in different tumor types. This activity was linked to a VEGFR-2 specific T-cell response and was accompanied by the destruction of the tumor vasculature and increased immune cell infiltration. In pre-clinical studies, VXM01 appeared to be safe and well tolerated. A double-blind, randomized, placebo-controlled study in 72 patients with advanced pancreatic cancer confirmed that VXM01 was safe and well tolerated and demonstrated the activation of VEGFR-2 specific cytotoxic T-cells after VXM01 treatment, which was associated with improved patient survival.
VAXIMM is a privately held, Swiss and German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells (so-called killer cells) to target specific structures of the tumor. VAXIMM’s lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. In addition to VXM01, VAXIMM has a pipeline of complementary development candidates targeting different tumor structures. VAXIMM’s investors include BB Biotech Ventures, Merck Serono Ventures, Sunstone Capital and BioMed Partners. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s clinical operations. For more information, please see www.vaximm.com.
Dr. Heinz Lubenau
Tel.: +49 621 8359 687 0
MC Services AG
Katja Arnold, Shaun Brown
Tel: +49 89 210228-0